In the Sweet Spot · · Zoetis (ZTS) · Healthcare
Zoetis: quality near the top of our coverage, sitting in the sweet spot near its 52-week low
Zoetis combines a 95.1 quality percentile with an 18.5% projected return, landing in our sweet spot while trading just above its 52-week low ahead of an August 6 earnings report.
Zoetis (ZTS) was Manifest Investing's In the Sweet Spot daily stock pick for July 9, 2026. At the time of the pick, Zoetis carried a quality percentile of 95 and a projected annual return (PAR) of 18.5% against a MIPAR of 8.8%, placing it inside the sweet spot of 13.8% to 18.8%.
Key metrics at the time of the pick
- Quality percentile
- 95
- Projected annual return (PAR)
- 18.5%
- MIPAR (median PAR of coverage)
- 8.8%
- PROVE
- 12.8%
- Core score (of 300)
- 284
- Financial strength (of 100)
- 91
- EPS stability (of 100)
- 97.7
- Sales growth forecast
- 5.3%
- P/E ratio
- 17.5
- Price at pick
- $75.10
- 52-week low
- $71.47
- 52-week high
- $161.77
- Above 52-week low
- 5.1%
- Below 52-week high
- 53.6%
- Dividend yield
- 2.6%
- Projected yield
- 1.7%
- In the sweet spot
- Yes
- Triple play
- No
Why Zoetis stands out today
Zoetis (ZTS), the animal-health company spun out of Pfizer, screens today as one of the more interesting combinations of quality and projected return in our coverage. At a quality percentile of 95.1 (ranking ahead of roughly 95% of the companies we follow), Zoetis carries a Projected Annual Return (PAR) of 18.5%. PAR is our forward-looking estimate of annualized total return over roughly the next five years, built from a sales growth forecast, projected margins, and the P/E the market is likely to assign at the end of that stretch. With MIPAR (the median PAR across everything we follow) at 8.8%, the sweet spot we look for runs from 13.8% to 18.8% (MIPAR + 5 to +10 points). Zoetis’s 18.5% PAR puts it right near the top of that band, comfortably inside it.
A few supporting data points:
- Financial strength: 91 out of 100, a solid balance sheet reading.
- EPS stability: 97.7 out of 100, among the smoothest earnings track records we track.
- Core Score: 284 out of 300 (quality percentile + financial strength + EPS stability, each on their own 0-100 scale). Anything above 225 is the threshold we associate with “core holding” candidates, so 284 is well past it.
- Price positioning: shares sit at $75.10, just 5.1% above the 52-week low of $71.47 and 53.6% below the 52-week high of $161.77. That’s a meaningful pullback from the annual high, and it’s part of why the projected return looks as attractive as it does. PAR moves inversely to price: when the price falls and the fundamentals hold, the projected return rises.
- Growth and yield: the growth forecast embedded in the model is 5.3%, current dividend yield is 2.65%, with a projected yield of 1.7%. The current P/E is 17.5.
Why today specifically: Zoetis reports next-quarter earnings on August 6, 2026, giving investors a concrete near-term checkpoint. On the operating side, Zoetis also picked up European Commission approval this week for a new poultry vaccine, one small data point on the pipeline side of the business.
For context, the Wall Street consensus price target across covering analysts is $110.57, per our data aggregator. We mention that as an outside reference point only, not as a blend with our own PAR methodology, which are two different lenses on the stock.
As always, this is a research lens, not a recommendation. The combination of high quality, a sweet-spot PAR, and proximity to a 52-week low is the kind of setup worth studying more closely, not a signal to act on by itself.
Sources
Zoetis has also been the In the Sweet Spot pick on: August 14, 2026.
About In the Sweet Spot
Manifest Investing's daily stock pick: one high-quality company whose projected annual return (PAR) sits in the sweet spot above the market median (MIPAR). Each pick pairs Manifest Investing's quality percentile with its projected annual return (PAR); the sweet spot runs from MIPAR + 5 to MIPAR + 10 percentage points. Browse every pick in the archive.
In the Sweet Spot is educational and is not investment advice or a recommendation to buy or sell any security. Figures reflect Manifest Investing's methodology as of the pick date.